IAA
GALT icon

Independent Advisor Alliance’s Galectin Therapeutics GALT Stock Holding History

Independent Advisor Alliance’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-36,100
Closed -$59.9K – 714
2023
Q4 		$59.9K Hold
36,100
– – ﹤0.01% 660
2023
Q3 		$69.3K Hold
36,100
– – ﹤0.01% 632
2023
Q2 		$52K Hold
36,100
– – ﹤0.01% 649
2023
Q1 		$75.8K Buy
+36,100
New +$58.3K ﹤0.01% 640

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Independent Advisor Alliance's GALT Position: Q1 2024 in Review

Independent Advisor Alliance sold out of Galectin Therapeutics (GALT) in Q1 2024, closing a stake of 36,100 shares — an estimated $59.9K sold.

Independent Advisor Alliance first reported a position in GALT in Q1 2023 and held it in 4 quarters. The position peaked at $75.8K in Q1 2023. 59 funds tracked by Wall St. Rank hold GALT as of Q1 2024.

  • Independent Advisor Alliance reported no remaining Galectin Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Independent Advisor Alliance sold 36,100 Galectin Therapeutics shares in Q1 2024, an estimated $59.9K.
  • Independent Advisor Alliance first reported a position in Galectin Therapeutics in Q1 2023 and held it in 4 quarters.
  • Independent Advisor Alliance's Galectin Therapeutics position peaked at $75.8K in Q1 2023.
  • 59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2024.

Based on Independent Advisor Alliance's 13F filing for Q1 2024, filed 8 May 2024.